WO2008054215A3 - Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction - Google Patents

Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction Download PDF

Info

Publication number
WO2008054215A3
WO2008054215A3 PCT/NL2007/050535 NL2007050535W WO2008054215A3 WO 2008054215 A3 WO2008054215 A3 WO 2008054215A3 NL 2007050535 W NL2007050535 W NL 2007050535W WO 2008054215 A3 WO2008054215 A3 WO 2008054215A3
Authority
WO
WIPO (PCT)
Prior art keywords
androstanediol
alpha
optionally
combination
sexual dysfunction
Prior art date
Application number
PCT/NL2007/050535
Other languages
French (fr)
Other versions
WO2008054215A2 (en
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Lange Robertus Petrus Johannes De
Original Assignee
Emotional Brain Bv
Jan Johan Adriaan Tuiten
Bloemers Johannes Martinus Mar
De Lange Robertus Petrus Johan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR20157004613A priority Critical patent/KR20150038251A/en
Application filed by Emotional Brain Bv, Jan Johan Adriaan Tuiten, Bloemers Johannes Martinus Mar, De Lange Robertus Petrus Johan filed Critical Emotional Brain Bv
Priority to CA2668320A priority patent/CA2668320C/en
Priority to NZ577392A priority patent/NZ577392A/en
Priority to KR1020097011486A priority patent/KR20090111803A/en
Priority to EP07834665A priority patent/EP2086548A2/en
Priority to BRPI0717963-4A2A priority patent/BRPI0717963A2/en
Priority to AU2007314736A priority patent/AU2007314736B2/en
Priority to US12/513,357 priority patent/US8648060B2/en
Priority to JP2009535228A priority patent/JP2010509213A/en
Priority to MX2009004695A priority patent/MX2009004695A/en
Priority to RU2009120992/15A priority patent/RU2491073C2/en
Publication of WO2008054215A2 publication Critical patent/WO2008054215A2/en
Publication of WO2008054215A3 publication Critical patent/WO2008054215A3/en
Priority to IL198460A priority patent/IL198460A/en
Priority to NO20092146A priority patent/NO20092146L/en
Priority to US14/147,393 priority patent/US20140121189A1/en
Priority to PH12014501440A priority patent/PH12014501440A1/en
Priority to IL237786A priority patent/IL237786A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha- androstanediol, preferably in combination with a 5-HT1A agonist. Optionally, said 3-alpha-androstanediol and said 5HT1a agonist are further combined with a type 5 phosphodiesterase (PDE5) inhibitor.
PCT/NL2007/050535 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction WO2008054215A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
US12/513,357 US8648060B2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction
AU2007314736A AU2007314736B2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-HT1A agonist, in the treatment of sexual dysfunction
CA2668320A CA2668320C (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
NZ577392A NZ577392A (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
KR1020097011486A KR20090111803A (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
EP07834665A EP2086548A2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
BRPI0717963-4A2A BRPI0717963A2 (en) 2006-11-03 2007-11-02 USE OF 3-ALPHA-ANDROSTANODIOL, PHARMACEUTICAL COMPOSITION, AND, PARTS KIT.
KR20157004613A KR20150038251A (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
RU2009120992/15A RU2491073C2 (en) 2006-11-03 2007-11-02 Using 3-androstanediol optionally in combination with 5-ht1a antagonist for treating sexual dysfunction
MX2009004695A MX2009004695A (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction.
JP2009535228A JP2010509213A (en) 2006-11-03 2007-11-02 Use of 3-α-androstanediol, optionally in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction
IL198460A IL198460A (en) 2006-11-03 2009-04-30 Use of 3-alpha-androstanediol and a 5-ht1a agonist in the preparation of a medicament for the on demand treatment of sexual dysfunction
NO20092146A NO20092146L (en) 2006-11-03 2009-06-03 Use of 3-ALFA-Androstiol, optionally in combination with a 5-HT1A agonist, in the treatment of sexual dysfunction
US14/147,393 US20140121189A1 (en) 2006-11-03 2014-01-03 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
PH12014501440A PH12014501440A1 (en) 2006-11-03 2014-06-20 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
IL237786A IL237786A0 (en) 2006-11-03 2015-03-16 Use of 3-alpha-androstanediol, optionally combination with a 5-ht1a agonist, in the treatment of sexual dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076976.7 2006-11-03
EP06076976A EP1925307A1 (en) 2006-11-03 2006-11-03 Use of 3-alpha-androstanediol in the treatment of sexual dysfunction

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/513,357 A-371-Of-International US8648060B2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction
US14/147,393 Division US20140121189A1 (en) 2006-11-03 2014-01-03 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
WO2008054215A2 WO2008054215A2 (en) 2008-05-08
WO2008054215A3 true WO2008054215A3 (en) 2009-04-09

Family

ID=37846101

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/NL2007/050535 WO2008054215A2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
PCT/NL2007/050534 WO2008054214A2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
PCT/NL2007/050533 WO2008054213A2 (en) 2006-11-03 2007-11-02 Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/NL2007/050534 WO2008054214A2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
PCT/NL2007/050533 WO2008054213A2 (en) 2006-11-03 2007-11-02 Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction

Country Status (28)

Country Link
US (10) US8575139B2 (en)
EP (5) EP1925307A1 (en)
JP (8) JP2010509212A (en)
KR (6) KR20090115113A (en)
CN (6) CN103381270A (en)
AU (3) AU2007314736B2 (en)
BR (3) BRPI0717963A2 (en)
CA (3) CA2668320C (en)
CY (1) CY1117191T1 (en)
DK (1) DK2086544T3 (en)
ES (1) ES2561946T3 (en)
HK (1) HK1135038A1 (en)
HR (1) HRP20160108T1 (en)
HU (1) HUE026752T2 (en)
IL (5) IL198461A (en)
ME (1) ME02410B (en)
MX (3) MX2009004695A (en)
NO (3) NO20092146L (en)
NZ (3) NZ577393A (en)
PH (2) PH12014501440A1 (en)
PL (1) PL2086544T3 (en)
PT (1) PT2086544E (en)
RS (1) RS54541B1 (en)
RU (4) RU2464027C2 (en)
SI (1) SI2086544T1 (en)
UA (4) UA101948C2 (en)
WO (3) WO2008054215A2 (en)
ZA (3) ZA200903837B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1750766E (en) 2004-05-11 2013-09-30 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
CN109908099B (en) * 2011-05-13 2021-10-29 Eb Ip希博里塔布斯有限责任公司 Drug delivery system
HUE055562T2 (en) 2011-11-23 2021-11-29 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (en) 2014-01-30 2015-12-09 国立大学法人高知大学 Method for producing nickel powder
JP5936783B2 (en) 2014-02-21 2016-06-22 国立大学法人高知大学 Method for producing nickel powder
JP6406613B2 (en) 2014-04-15 2018-10-17 住友金属鉱山株式会社 Method for producing nickel powder with reduced concentration of carbon and sulfur
CN103947533B (en) * 2014-05-15 2015-12-16 青岛理工大学 The magnetized drinking water batch production bean sprouts production system that growing environment is controlled
RU2600845C2 (en) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Use of oxathriazolo-5-olate for treating sexual disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
WO2005107810A2 (en) * 2004-05-11 2005-11-17 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
RU2152787C2 (en) * 1994-06-02 2000-07-20 Дан Рига Drug against stress, activity level decrease and ageing and method of its preparing
BR9408581A (en) 1994-06-02 1997-08-26 Dan Riga Anti-stress, anti-incapacitation and anti-aging medication and process for its production
US5698560A (en) 1995-03-01 1997-12-16 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
WO1996028142A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Method and kit for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2219082A1 (en) 1995-05-15 1996-11-21 Beth Israel Deaconess Medical Center, Inc. Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
DE69833254T2 (en) 1997-06-23 2006-11-02 Cellegy Pharmaceuticals, Inc., Brisbane MICRODOSIS THERAPY OF VASCULAR EXPOSURE BY NO-DONORS
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6246436B1 (en) 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6632419B2 (en) 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
CA2377339A1 (en) 1999-06-17 2000-12-28 Armin Johannes Becker Administration of growth hormone (hgh) for the therapy of sexual functional disorders
RU2180591C2 (en) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Agent for treatment of men with sexual disorders
DE10016548A1 (en) 2000-04-03 2001-10-11 Bayer Ag Polyurethane dispersions
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
ATE460939T1 (en) 2000-08-30 2010-04-15 Unimed Pharmaceuticals Llc METHOD FOR TREATING ERECTIVE DISORDER AND INCREASE LIBIDO IN MEN
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
SK287066B6 (en) 2000-09-29 2009-11-05 Solvay Pharmaceuticals B. V. Pharmaceutical formulation having a prolonged release and method of preparing this formulation
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
NZ526925A (en) * 2000-12-15 2005-03-24 Pfizer Treatment of male sexual dysfunction
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
EA006154B1 (en) 2001-03-28 2005-10-27 Пфайзер Инк. N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
ATE319426T1 (en) 2003-11-11 2006-03-15 Mattern Udo NASAL FORMULATION WITH CONTROLLED RELEASE OF SEXUAL HORMONES
KR20070014184A (en) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 New pharmaceutical compositions for the treatment of sexual disorders ii
KR20080016552A (en) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. Method of increasing testosterone and related steroid concentrations in women
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US8592477B2 (en) 2007-11-28 2013-11-26 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
WO2005107810A2 (en) * 2004-05-11 2005-11-17 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORALI GABRIELA ET AL: "Mechanisms regulating male sexual behavior in the rat: Role of 3-alpha- and 3-beta-androstanediols", BIOLOGY OF REPRODUCTION, vol. 51, no. 3, 1994, pages 562 - 571, XP002514516, ISSN: 0006-3363 *

Also Published As

Publication number Publication date
ZA200903835B (en) 2010-10-27
PL2086544T3 (en) 2016-07-29
HK1135038A1 (en) 2010-05-28
EP2086544A2 (en) 2009-08-12
RU2012125827A (en) 2013-12-27
JP2015157849A (en) 2015-09-03
PH12014501821B1 (en) 2016-02-01
WO2008054213A3 (en) 2009-04-09
US20100093680A1 (en) 2010-04-15
IL198459A (en) 2016-11-30
ES2561946T3 (en) 2016-03-01
JP2014111608A (en) 2014-06-19
US8653051B2 (en) 2014-02-18
CN101563086B (en) 2013-11-27
AU2007314735A1 (en) 2008-05-08
US8575139B2 (en) 2013-11-05
AU2007314734B2 (en) 2014-01-30
IL248563A0 (en) 2016-12-29
JP6357131B2 (en) 2018-07-11
IL198459A0 (en) 2010-02-17
ME02410B (en) 2016-09-20
KR20090115113A (en) 2009-11-04
SI2086544T1 (en) 2016-04-29
IL198460A (en) 2016-11-30
NO20092146L (en) 2009-07-21
CN103381270A (en) 2013-11-06
BRPI0717856A2 (en) 2013-10-29
KR20090111802A (en) 2009-10-27
JP2010509213A (en) 2010-03-25
CN104524580A (en) 2015-04-22
CA2668320A1 (en) 2008-05-08
CN101563086A (en) 2009-10-21
AU2007314734A1 (en) 2008-05-08
US20100160270A1 (en) 2010-06-24
WO2008054215A2 (en) 2008-05-08
PT2086544E (en) 2016-03-17
IL237786A0 (en) 2015-05-31
US20160082018A1 (en) 2016-03-24
US8648060B2 (en) 2014-02-11
DK2086544T3 (en) 2016-02-08
EP1925307A1 (en) 2008-05-28
UA115647C2 (en) 2017-12-11
EP2086545A2 (en) 2009-08-12
CA2668316A1 (en) 2008-05-08
EP2086544B1 (en) 2015-12-23
JP2010509212A (en) 2010-03-25
US20140121190A1 (en) 2014-05-01
BRPI0717963A2 (en) 2013-11-05
US9597335B2 (en) 2017-03-21
CA2668316C (en) 2014-06-10
KR20090111803A (en) 2009-10-27
US20100152145A1 (en) 2010-06-17
CA2668320C (en) 2014-06-10
KR20150099620A (en) 2015-08-31
US10314848B2 (en) 2019-06-11
US20170157142A1 (en) 2017-06-08
NZ577393A (en) 2012-11-30
BRPI0718396A2 (en) 2013-11-26
UA103592C2 (en) 2013-11-11
CN103599536A (en) 2014-02-26
RU2491073C2 (en) 2013-08-27
ZA200903837B (en) 2010-08-25
IL248563B (en) 2018-11-29
WO2008054214A3 (en) 2009-04-09
MX2009004695A (en) 2009-06-05
US20190262359A1 (en) 2019-08-29
RU2009120990A (en) 2010-12-10
NO20092145L (en) 2009-07-21
AU2007314736A1 (en) 2008-05-08
US9211334B2 (en) 2015-12-15
KR20160124246A (en) 2016-10-26
JP2010509211A (en) 2010-03-25
WO2008054214A2 (en) 2008-05-08
IL198460A0 (en) 2010-02-17
US20140038929A1 (en) 2014-02-06
CA2668317A1 (en) 2008-05-08
RS54541B1 (en) 2016-06-30
CN101557812A (en) 2009-10-14
JP2014055142A (en) 2014-03-27
CA2668317C (en) 2016-02-09
CY1117191T1 (en) 2017-04-05
MX2009004696A (en) 2009-06-05
NZ577390A (en) 2012-12-21
KR20150038251A (en) 2015-04-08
AU2007314735B2 (en) 2014-01-16
PH12014501440A1 (en) 2016-02-01
RU2009120988A (en) 2010-12-10
EP2937086A1 (en) 2015-10-28
RU2464027C2 (en) 2012-10-20
US8669242B2 (en) 2014-03-11
PH12014501821A1 (en) 2016-02-01
WO2008054213A2 (en) 2008-05-08
UA100119C2 (en) 2012-11-26
JP2017132809A (en) 2017-08-03
EP2086548A2 (en) 2009-08-12
RU2463054C2 (en) 2012-10-10
MX2009004693A (en) 2009-06-05
KR101796887B1 (en) 2017-11-10
ZA200903836B (en) 2010-08-25
NZ577392A (en) 2012-11-30
IL198461A0 (en) 2010-02-17
JP5748238B2 (en) 2015-07-15
NO343597B1 (en) 2019-04-08
HRP20160108T1 (en) 2016-03-25
IL198461A (en) 2017-08-31
RU2646447C2 (en) 2018-03-05
US20120277200A1 (en) 2012-11-01
RU2009120992A (en) 2010-12-10
UA101948C2 (en) 2013-05-27
JP2014001235A (en) 2014-01-09
KR101578224B1 (en) 2015-12-16
NO20092143L (en) 2009-07-02
US20140121189A1 (en) 2014-05-01
HUE026752T2 (en) 2016-07-28
CN101573119A (en) 2009-11-04
AU2007314736B2 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
WO2008054215A3 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
WO2005121321A3 (en) Compositions comprising female germline stem cells and methods of use thereof
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2007146124A3 (en) Deuterated tadalafil derivatives
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
EP1888091A4 (en) Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds
WO2007120651A3 (en) Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2008100933A3 (en) Reducing side effects of tramadol
WO2006029398A8 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
AP2008004437A0 (en) Pyrazolo Ä4,3-DÜ pyrimidin-5-yl) derivative used as PDE5 inhibitors
PL2185561T3 (en) 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo(1,2-a)-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof
AP2380A (en) Use of surfactants in the production of metal.
EA200702201A1 (en) ROFLUMILAST FOR TREATMENT OF PULMONARY HYPERTENSION
WO2006041808A3 (en) Tafi inhibitors and their use to treat pulmonary fibrosis
WO2006102126A3 (en) Inhibitors of isoprenylcysteine carboxyl methyltransferase
WO2008063791A3 (en) Composites and methods of preparation and use thereof
EP1709445A4 (en) Itpks as modifiers of the igfr pathway and methods of use
TW200716099A (en) Hydrates of alkaline earth metal salts of irbesartan and their preparation
WO2005023288A8 (en) Treatment of fibrotic disease
WO2005018620A3 (en) Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
AU2006315663A8 (en) KIFS as modifiers of the RHO pathway and methods of use
AU311277S (en) Hammer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780049131.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 198460

Country of ref document: IL

Ref document number: 12009500845

Country of ref document: PH

Ref document number: MX/A/2009/004695

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009535228

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2668320

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007314736

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3130/CHENP/2009

Country of ref document: IN

Ref document number: 2007834665

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009120992

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A200905652

Country of ref document: UA

Ref document number: 577392

Country of ref document: NZ

Ref document number: 1020097011486

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007314736

Country of ref document: AU

Date of ref document: 20071102

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07834665

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12513357

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0717963

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090504

WWE Wipo information: entry into national phase

Ref document number: 1020157004613

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 237786

Country of ref document: IL